# Fate Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Fate Therapeutics, Inc). ## Overview Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs). Its core business is to engineer renewable master cell lines and turn them into uniform T-cell and NK-cell product candidates designed for oncology and autoimmune diseases. ## Products & services • iPSC-derived CAR T-cell product candidates • iPSC-derived NK-cell product candidates • Cellular programming platform for off-the-shelf therapies • FT819 autoimmune program for SLE and lupus nephritis • Preclinical and clinical development collaborations • Internal GMP manufacturing capabilities - **Cell therapy product candidates** (0%) — Clinical and preclinical off-the-shelf iPSC-derived cell therapies for cancer and autoimmune disease. - **Collaboration revenue** (85%) — Upfront payments, research funding, and milestone-related revenue from strategic partners. - **Government grants** (15%) — Grant funding supporting preclinical, IND-enabling, and development activities. - iPSC-derived CAR T-cell product candidates - iPSC-derived NK-cell product candidates - Cellular programming platform for off-the-shelf therapies - FT819 autoimmune program for SLE and lupus nephritis - Preclinical and clinical development collaborations - Internal GMP manufacturing capabilities ## Customers Fate does not yet sell approved therapies commercially; its current counterparties are pharmaceutical partners, grant providers, and clinical research collaborators. If its programs succeed, the end customers will be physicians, hospitals, and specialty treatment centers treating patients with hematologic cancers and autoimmune diseases. - **Strategic collaboration partners** (primary) — Biopharma companies that pay for joint development, access to IP, and milestone-based progress on product candidates. - **Government and research grant agencies** (secondary) — Public funding sources that support preclinical and IND-enabling work for selected programs. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that enroll patients and generate the clinical data needed for approval. - **Future specialty physicians** (emerging) — Autoimmune and oncology specialists who would prescribe approved cell therapies if commercialized. - **Future treatment centers** (emerging) — Hospitals and outpatient centers that would administer off-the-shelf cell therapies after approval. - Pharmaceutical partners funding joint development and licensing - Government and research grant providers supporting R&D - Clinical investigators and trial sites running studies - Future physicians treating autoimmune and oncology patients - Future hospitals and specialty centers administering cell therapy ## Geography The company is headquartered in San Diego, California and conducts substantially all of its operations in the United States. Its current business is primarily U.S.-based, but management has also disclosed plans to expand clinical investigation into the U.K. and EU for FT819, which would broaden regulatory and trial exposure. - **United States** (100%) — Substantially all operations are based in the U.S.; no country revenue disclosed. - Headquartered in San Diego, California - Substantially all operations are conducted in the United States - Clinical development is currently centered in U.S. trial sites - FT819 trials expanded to the U.K. and EU in 2025 - Future commercialization could require multi-region regulatory execution ## Strategy Fate’s strategy is to advance a differentiated iPSC platform into first-in-class or best-in-class off-the-shelf cell therapies, with a near-term focus on FT819 in autoimmune disease. The company is also pursuing regulatory acceleration, broader geographic trial access, and collaboration funding to extend runway while it moves programs toward registrational studies and eventual BLA filing. - **Advance FT819 through clinical and regulatory milestones** (short-term) — This program is the clearest path to value creation and potential first commercial approval. - **Expand ex-U.S. clinical development** (medium-term) — Broader trial geography can speed enrollment, diversify regulatory pathways, and support global commercialization. - **Preserve cash and secure non-dilutive funding** (short-term) — As a clinical-stage company with no product revenue, financing access is essential to sustain development. - Advance FT819 in SLE and lupus nephritis toward registrational development - Use RMAT designation to accelerate FDA interaction and review - Expand clinical trials into the U.K. and EU - Leverage off-the-shelf iPSC manufacturing to improve accessibility - Fund development through collaborations, grants, and capital raises ## Risks The company faces the typical clinical-stage biotech risks of trial failure, regulatory delay, and uncertain market acceptance, all of which can prevent commercialization and prolong losses. Its cell-therapy manufacturing process is complex, and the business also depends on access to combination drugs, partner funding, and reimbursement support if any product is approved. - **Clinical development failure or delay** [high] — The company has no approved products, so setbacks in trials can eliminate or postpone future revenue. - **Manufacturing and regulatory complexity** [high] — iPSC-derived cell therapies require tightly controlled GMP processes and may face additional FDA requirements. - **Dependence on combination-drug access** [medium] — Some programs require monoclonal antibodies or other biologics that must be available on acceptable terms. - **Market acceptance and reimbursement uncertainty** [high] — Autoimmune patients may be reluctant to accept cell-therapy risk without strong evidence and coverage support. - **Financing and dilution risk** [high] — The company expects meaningful revenue only after approval and must fund operations externally. - Clinical trials may be delayed, modified, or fail to show efficacy - Cell therapy manufacturing is complex and highly regulated - Combination therapy programs depend on third-party drug supply - Commercial adoption may be limited by physician and patient caution - Funding risk remains high because the company has no product sales ## Accounting The most important accounting issue is revenue recognition from collaboration agreements and grants, since the company has not generated product sales. Investors should also watch estimates tied to collaboration cost obligations, lease accounting, stock-based compensation, and fair value measurements for milestone-related liabilities, all of which can move reported results materially. - **Collaboration revenue recognition** — Can create lumpy quarterly revenue and affect comparability - **Fair value of milestone liabilities** — Changes can affect operating expenses or liabilities - **Stock-based compensation** — Affects operating loss and non-cash expense trends - **Lease accounting** — Affects balance sheet leverage and operating expense presentation - **Estimated collaboration costs** — Can alter accrued expenses and period expense recognition - Revenue is driven by collaboration agreements and government grants - Collaboration revenue depends on milestone and research activity timing - Fair value estimates affect milestone-related liabilities - Stock-based compensation is a meaningful non-cash expense - Lease and accrued expense estimates affect reported liabilities --- *Last updated: 2026-04-28T20:06:10.694663+00:00*